71 related articles for article (PubMed ID: 11888922)
1. Cellular processing of a multibranched lysine core with tumor antigen peptides and presentation of peptide epitopes recognized by cytotoxic T lymphocytes on antigen-presenting cells.
Ota S; Ono T; Morita A; Uenaka A; Harada M; Nakayama E
Cancer Res; 2002 Mar; 62(5):1471-6. PubMed ID: 11888922
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia.
Manki A; Ono T; Uenaka A; Seino Y; Nakayama E
Cancer Res; 1998 May; 58(9):1960-4. PubMed ID: 9581839
[TBL] [Abstract][Full Text] [Related]
3. Class II MHC molecules can use the endogenous pathway of antigen presentation.
Nuchtern JG; Biddison WE; Klausner RD
Nature; 1990 Jan; 343(6253):74-6. PubMed ID: 1967486
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of tumor antigen pRL1a specific CD8 T cells in spleen cells from syngeneic BALB/c, semiallogeneic (BALB/c x C57BL/6)F1 and allogeneic C57BL/6 mice.
Hata H; Uenaka A; Takada I; Kenjo A; Takahashi M; Ono T; Fujita T; Nakayama E
Int J Oncol; 2002 May; 20(5):1019-25. PubMed ID: 11956599
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells.
Robson NC; Donachie AM; Mowat AM
Eur J Immunol; 2008 May; 38(5):1238-46. PubMed ID: 18398931
[TBL] [Abstract][Full Text] [Related]
6. Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape.
Matsuo M; Wada H; Honda S; Tawara I; Uenaka A; Kanematsu T; Nakayama E
J Immunol; 1999 Jun; 162(11):6420-5. PubMed ID: 10352255
[TBL] [Abstract][Full Text] [Related]
7. Introduction of exogenous antigens into the MHC class I processing and presentation pathway by Drosophila antennapedia homeodomain primes cytotoxic T cells in vivo.
Schutze-Redelmeier MP; Gournier H; Garcia-Pons F; Moussa M; Joliot AH; Volovitch M; Prochiantz A; Lemonnier FA
J Immunol; 1996 Jul; 157(2):650-5. PubMed ID: 8752913
[TBL] [Abstract][Full Text] [Related]
8. Diversity of epitopes recognized by cytotoxic T lymphocytes that are specific for rejection antigen peptide pRL1a presented on BALB/c leukemia RL Male 1.
Yokoi T; Uenaka A; Ono T; Onizuka S; Inoue H; Nakayama E
Int Immunol; 1997 Aug; 9(8):1195-201. PubMed ID: 9263017
[TBL] [Abstract][Full Text] [Related]
9. Murine leukemia RL male 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL).
Uenaka A; Nakayama E
Cancer Sci; 2003 Nov; 94(11):931-6. PubMed ID: 14611667
[TBL] [Abstract][Full Text] [Related]
10. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ
Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087
[TBL] [Abstract][Full Text] [Related]
11. Possible involvement of autoreactive CD4 T cells in generation of cytotoxic T lymphocytes on in vitro stimulation with H-2 class I-binding tumor antigen peptide.
Honda S; Wada H; Uenaka A; Nakayama E
Int Immunol; 1998 Aug; 10(8):1167-74. PubMed ID: 9723703
[TBL] [Abstract][Full Text] [Related]
12. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
13. Downmodulation of antigen presentation by H2-O in B cell lines and primary B lymphocytes.
Brocke P; Armandola E; Garbi N; Hämmerling GJ
Eur J Immunol; 2003 Feb; 33(2):411-21. PubMed ID: 12645938
[TBL] [Abstract][Full Text] [Related]
14. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.
Chakraborty NG; Stevens RL; Mehrotra S; Laska E; Taxel P; Sporn JR; Schauer P; Albertsen PC
Cancer Immunol Immunother; 2003 Aug; 52(8):497-505. PubMed ID: 12783216
[TBL] [Abstract][Full Text] [Related]
15. Cross-presentation: underlying mechanisms and role in immune surveillance.
Rock KL; Shen L
Immunol Rev; 2005 Oct; 207():166-83. PubMed ID: 16181335
[TBL] [Abstract][Full Text] [Related]
16. MHC class I-associated presentation of exogenous peptides is not only enhanced but also prolonged by linking with a C-terminal Lys-Asp-Glu-Leu endoplasmic reticulum retrieval signal.
Wang L; Wu YZ; Chen A; Zhang JB; Yang Z; Niu W; Geng M; Ni B; Zhou W; Zou LY; Jiang M
Eur J Immunol; 2004 Dec; 34(12):3582-94. PubMed ID: 15495159
[TBL] [Abstract][Full Text] [Related]
17. Bordetella pertussis adenylate cyclase delivers chemically coupled CD8+ T-cell epitopes to dendritic cells and elicits CTL in vivo.
Fayolle C; Bauche C; Ladant D; Leclerc C
Vaccine; 2004 Dec; 23(5):604-14. PubMed ID: 15542180
[TBL] [Abstract][Full Text] [Related]
18. Defining MHC class II T helper epitopes for WT1 tumor antigen.
Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of serine-peptidase activity enhances the generation of a survivin-derived HLA-A2-presented CTL epitope in colon-carcinoma cells.
Preta G; Marescotti D; Fortini C; Carcoforo P; Castelli C; Masucci M; Gavioli R
Scand J Immunol; 2008 Dec; 68(6):579-88. PubMed ID: 19000094
[TBL] [Abstract][Full Text] [Related]
20. Assessing vaccine potency using TCRmimic antibodies.
Neethling FA; Ramakrishna V; Keler T; Buchli R; Woodburn T; Weidanz JA
Vaccine; 2008 Jun; 26(25):3092-102. PubMed ID: 18353510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
